[1] 文洁, 朱德增. 中晚期原发性肝癌患者的危险因素分析.中国现代医学杂志,2011,21: 841-845.
[2] 吴孟超.关于降低肝癌术后复发率之我见.中国实用外科杂志,2012,32: 795-796.
[3] Nakamoto Y, Mizukoshi E, Kitahara M, et al. Prolonged recurrence-free survival following OK 432-stimulated dendritic cell transfer intohepatocellular carcinoma during transarterial embolization. Clin Exp Immunol, 2011, 163: 165-177.
[4] 康军,齐乃新,王天权,等.三维适形放疗联合肝动脉化疗栓塞治疗不能手术的原发性肝癌的疗效研究.现代肿瘤医学,2013,21:1834-1836.
[5] Chok KS, Cheung TT, Chan SC, et al. Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis. World J Surg, 2014,38: 490-496.
[6] El-Serag HB. Epidemiology of viral hepatitis and hepatocellular Carcinoma. Gastroenterology, 2012,142: 1264-1273.
[7] 王可武,王秀明,樊娟,等.国人精确放疗联合经肝动脉化疗栓塞术治疗原发性肝癌疗效的 Meta分析.现代肿瘤医学,2013,21:351-355.
[8] Tang QH, Li AJ, Yang GM, et al. Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study. World J Surg, 2013,37:1362-1370.
[9] Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein TumorThrombosis: A Prospective Comparative Study. Ann Surg Oncol, 2011,18: 413-420.
[10] 吴杰,宋磊,赵丹懿,等. 伊立替康经肝动脉栓塞化疗对不可切除肝癌患者生存期的影响. 中华普通外科杂志,2014,29: 534-537.
[11] 徐国斌,熊斌,刘骏方,等.原发性肝癌合并肝动静脉瘘的介入栓塞治疗策略及疗效探讨.临床放射学杂志,2011,30:82-85.
[12] 柯群刚,黄继超,刘细国,等.导管肝动脉化疗栓塞治疗中晚期肝癌对患者肝脏功能的影响.中华普外科手术学杂志(电子版),2015,9:33-35.
[13] 沈玲,朱海超,黄建锋,等.TACE 治疗中晚期原发性肝癌 108 例生存分析.肿瘤防治研究,2011,38:1163-1166.
[14] 何选秋,李咏茵,张小勇,等.自然杀伤细胞在肝脏疾病中的作用.肝脏,2014,19:128-131.
[15] 狄纪君,郭卫东,张惠洁,等.TACE 联合热疗治疗原发性肝癌的临床观察.临床肿瘤学杂志,2012,17:42-46. |
